Research Article
ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population
Table 4
Distribution of ABCB1 genotypes frequencies in drug-responsive and drug-resistant patients.
| SNP | ABCB1 genotype | Drug-resistant patients () | Drug-responsive patients () | ORs | 95% CI | value | 2 | | % | | % |
| ABCB1 C1236T | CC vs. CT+TT | 6 | 12 | 17 | 34 | 0.265 | 0.094-0.745 | 0 .012 | 6.830 | CT vs. CC+TT | 18 | 56 | 27 | 54 | 0.479 | 0.215-1.068 | 0.072 | 3.270 | TT vs. CC+CT | 26 | 52 | 6 | 12 | 7.944 | 2.872-21.978 | ≤0.001 | 18.380 | TT vs. CC | 26 | 52 | 6 | 12 | 12.278 | 3.393-44.433 | ≤0.001 | 16.740 | CT vs. CC | 18 | 56 | 27 | 54 | 1.889 | 0.625-5.705 | 0.260 | 2.890 | TT vs. CT | 26 | 52 | 6 | 12 | 6.500 | 2.231-18.940 | ≤0.001 | 12.990 |
| ABCB1 G2677T | GG vs. GT+TT | 10 | 20 | 3 | 6 | 3.917 | 1.008-15.220 | 0.049 | 4.330 | GT vs. GG+TT | 13 | 26 | 41 | 82 | 0.077 | 0.030-0.201 | ≤0.001 | 31.560 | TT vs. GG+GT | 27 | 54 | 6 | 12 | 8.609 | 3.110-23.832 | ≤0.001 | 19.950 | TT vs. GG | 27 | 54 | 6 | 12 | 1.350 | 0.282-6.453 | 0.707 | 0.140 | GT vs. GG | 13 | 26 | 41 | 82 | 0.095 | 0.023-0.399 | 0.001 | 12.980 | TT vs. GT | 27 | 54 | 6 | 12 | 14.192 | 4.808-41.895 | 0.001 | 27.500 |
| ABCB1 C3435T | CC vs. CT+TT | 11 | 22 | 24 | 48 | 0.306 | 0.128-0.729 | 0.008 | 7.430 | CT vs. CC+TT | 9 | 18 | 20 | 40 | 0.329 | 0.132-0.824 | 0.018 | 5.880 | TT vs. CC+CT | 30 | 60 | 6 | 12 | 11 | 3.952-30.614 | ≤0.001 | 25 | TT vs. CC | 30 | 60 | 6 | 12 | 10.909 | 3.523-33.782 | ≤0.001 | 19.590 | CT vs. CC | 9 | 18 | 20 | 40 | 0.982 | 0.339-2.840 | 0.973 | 0 | TT vs. CT | 30 | 60 | 6 | 12 | 11.111 | 3.422-36.081 | ≤0.001 | 18.300 |
|
|
Values ( and %). ORs: odds ratio; 95% CI: confidence interval; significant value ≤ 0.05; 2: chi-square. |